Anti-inflammatory effect of wogonin on allergic responses in ovalbumin-induced allergic rhinitis in the mouse

Kyeong Ah Kim, Ph.D., Joo Hyun Jung, M.D., Ph.D., Yun Sook Choi, B.S., Il Gyu Kang, M.D., and Seon Tae Kim, M.D., Ph.D.

ABSTRACT

Background: Wogonin is commonly used for the treatment of allergic diseases. However, neither its precise effect in preventing allergic rhinitis (AR) nor its mechanism of action are known.

Objectives: In this study, the effect of wogonin on allergic responses in ovalbumin (OVA) induced AR was investigated in mice.

Methods: BALB/c mice were sensitized with intraperitoneal (i.p.) OVA and then challenged intranasally with OVA. Wogonin (10 and 30 mg/kg) was given to the treatment groups, and the effect of wogonin on the release of allergic inflammatory mediators, specifically OVA-specific immunoglobulin E (IgE) and inflammatory cytokines, was explored. Eosinophil infiltration and the levels of interleukin (IL) 5 and IL-13 were measured by immunohistochemistry.

Results: In mice with AR, wogonin decreased OVA-specific IgE levels in serum, and the levels of the cytokines IL-4, IL-5, IL-13, eotaxin, and RANTES in nasal lavage fluid. Serum levels of IL-4, IL-5, and IL-13 were lower in both groups of wogonin-pretreated mice than in the OVA group. A reduction in eosinophil infiltration of the nasal mucosa and inhibition of the expression of IL-5 and IL-13 were also noted in the treated groups.

Conclusion: Wogonin induced antiallergic effects in a murine model of AR by decreasing the infiltration of eosinophils and levels of T-helper type 2 cytokines. Thus, wogonin merits consideration as a therapeutic agent for treating AR.

(Allergy Rhinol 9:1–7, 2018; doi: 10.1177/2152656718764145)

Allergic rhinitis (AR) is a disease with a prevalence in the general population worldwide of 3–19%, but this is increasing in frequency.1,2 The prevalence of AR in Korea ranges from 6 to 10%, and this is also increasing.3,4 The typical symptoms of AR are nasal congestion, rhinorrhea, nasal itching, conjunctivitis, and disturbed olfaction, all of which create difficulties in school or work life, and are a major risk factor for asthma exacerbation.5–7 AR is caused by allergy mediators such as histamine, inflammatory cytokines, eosinophils, and mast cells.8 The AR reaction begins with the binding of mast cells to immunoglobulin E (IgE) receptors on the surface of basophils, which induces mast cell secretion of inflammatory cytokines and histamine.9 As a result, inflammatory cells and eosinophils migrate to the involved tissues.10

Current pharmacotherapy for AR includes corticosteroids, leukotriene receptor antagonists, mast cell stabilizers, and anticholinergics, but many patients seek complementary and alternative treatments, including the use of medicinal herbs, to decrease allergic inflammation.11,12 However, the precise effects and mechanisms of action of these approaches in reducing allergic asthma are unclear. Wogonin (5,7-dihydroxy-8-methoxyflavone) is a component of the dried root of Scutellaria baicalensis Georgi that has been used in China to treat liver disease, leukemia, and atherosclerosis.13,14 Antiangiogenesis, anticancer, and anti-inflammatory effects have also been described.15–17 In traditional Chinese medicine, wogonin is also used to treat allergies and inflammation, based on its toxin-removing and thermal cleansing properties,18 Antioxidative effects have also been described.19 In the present study, we examined the ability of wogonin to inhibit ovalbumin (OVA) induced allergic nasal symptoms and inflammatory cytokine release in a murine model of AR. We also investigated the mechanisms that underlie its effects.

METHODS

Animals

Six-week-old female BALB/c mice were purchased from Orient Bio Inc. (Seongnam, Korea). All animal experiments were carried out according to the Gachon University Animal Research Guidelines. The study was approved by Gachon University.
Group Classification and Development of an AR Model

The 6-week-old female BALB/c mice were divided into five groups (n = 7 per group): (1) the normal control group, (2) OVA-sensitized group, (3) wogonin 10 mg/kg group, (4) wogonin 30 mg/kg group, and (5) dexamethasone 4 mg/kg group. After the mice had been allowed to stabilize for 1 week, they were sensitized to OVA on days 0, 7, and 14 by an intraperitoneal (i.p.) injection of 50 mg of OVA (chicken egg albumin; Sigma-Aldrich Corp., St. Louis, MO) in 100 μL of phosphate-buffered saline solution that contained 2 mg of aluminum hydroxide (alum; Sigma-Aldrich). One week after the last injection, on day 21, the mice were challenged with 20 μL of phosphate-buffered saline solution that contained 50 μg/mL of OVA into the bilateral nasal cavities. From day 21 to day 31, the mice in the control and OVA groups were perorally administered saline solution, whereas those in the dexamethasone group received 4 mg/kg of dexamethasone (Sigma-Aldrich), and the wogonin groups were each orally administered 10 and 30 mg/kg of wogonin 1 hour before intranasal challenge of OVA under the same conditions. Wogonin was purchased from Alexis Biochemicals (San Diego, CA) and dissolved in dimethylsulfoxide. Dexamethasone is a steroid medication used in the treatment of skin diseases, severe allergies, and asthma. In this study, dexamethasone served as a positive control.

Collection of Serum and Nasal Lavage Fluid

Twenty-four hours after the last stimulation, the mice were euthanized while they were under anesthesia with isoflurane. Orbital puncture was used to obtain 300–400 μL of blood from the ophthalmic artery of each mouse. The blood samples were stored at 4°C for 2–4 hours and centrifuged, and the serum was collected. Nasal lavage fluid (NALF) was also collected in the posterior to anterior direction after irrigation with 1 mL of saline solution through an angiocatheter placed in the trachea. The lavage fluid was centrifuged (2000 rpm at 4°C), and 0.5 mL of the supernatant was stored at −70°C.

Extraction of Nasal Tissue Specimens

The decapitated head of each mouse was fixed in 10% paraformaldehyde for 24 hours. The extruded nasal tissue specimen was decalcified for 5 days and then sectioned from behind the upper incisor to 2 mm in front of the incisive papilla of the hard palate. After a paraffin block was prepared, slices of 4-μm thickness were obtained.

Measurement of OVA-Specific IgE in Serum

OVA-specific IgE levels were measured by using a mouse anti-OVA IgE enzyme-linked immunosorbent assay kit (Alpha Diagnostic International Inc., San Antonio, TX).

Measurement of Cytokine Levels in NALF and Serum

The levels of interleukin (IL) 4, IL-5, IL-13, eotaxin, and RANTES in NALF and serum were measured by using the respective enzyme-linked immunosorbent assay kits (BioSource International Inc., Camarillo, CA).

Hematoxylin and Eosin Staining

After deparaffinization of the samples, the nasal tissue specimens were stained with hematoxylin and eosin, and the numbers of inflammatory cells at five different sites were counted under ×400 magnification.

Immunohistochemical Staining

Nasal specimens were incubated with mouse monoclonal antihuman IL-4 antibody (BioVendor Laboratory
Medicine Inc., Brno, Czech Republic) and purified antimalouse/human IL-5 antibody (BioLegend, San Diego, CA), which was diluted 1:200, for 90 minutes at room temperature. The specimens were then incubated with goat-antimouse immunoglobulin (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hour at room temperature. Immunoreactive proteins were visualized by incubation with streptavidin-conjugated peroxidase for 15 minutes. After decolorization by using a 3,3-diaminobenzidine tetrahydrochloride solution, the samples were counterstained with hematoxylin. Control plates were processed similarly, but the primary antibody was omitted. The average ratio of the immunopositive area to the total area of epithelial cells in the nasal specimen was determined microscopically under ×100 magnification.

Statistical Analysis

The pathologic results regarding the nasal septum and cytokine levels in the NALF were analyzed statistically by using the Student’s t-test. A p value of <0.05 was considered to indicate statistical significance.

RESULTS

Effect of Wogonin on OVA-Specific IgE Levels in Serum of the AR Model

The mouse OVA-specific IgE level was 515.4 ± 88.5 U/mL in the OVA group, which was significantly higher than that of the normal control group (50.1 ± 20.1 U/mL). By contrast, mice administered either wogonin 30 mg/mL or dexamethasone had significantly lower OVA-specific IgE levels than the OVA group: 299.7 ± 60.0 U/mL and 274.6 ± 45.6 U/mL, respectively (Fig. 1).

Infiltration of Eosinophils in Nasal Mucosa

The number of infiltrated eosinophils was significantly higher in the OVA group than in the normal control group. In the wogonin and dexamethasone groups, eosinophil counts were significantly lower than in the OVA group (Fig. 2). These results indicated that treatment with wogonin effectively inhibited the infiltration of eosinophils.

Figure 2. Effects of wogonin on the infiltration of eosinophils (arrows) into nasal mucosa of mice with allergic rhinitis (AR). (A) Eosinophil infiltration of the nasal mucosa. Representative hematoxylin-and-eosin–stained sections of the nasal mucosa tissues are shown at a magnification of ×400. The infiltration of inflammatory cells was markedly reduced in mice in the wogonin-treated groups. (B) The number of eosinophils was significantly lower in the wogonin groups than in the OVA group.
Effect of Wogonin on Serum Cytokine Levels in the AR Model

Because allergic diseases are caused by the secretion of a series of Th2 cytokines, particularly IL-4, IL-5, and IL-13, we examined whether their levels were changed in OVA–wogonin-treated mice. The serum concentrations of IL-4, IL-5, and IL-13 were higher in the OVA group than in the control group (Fig. 3). Whereas the difference in serum IL-4 and IL-5 levels did not significantly differ between the wogonin and dexamethasone groups, IL-13 levels in the wogonin groups were significantly lower than in the OVA group.

Effect of Wogonin on Cytokine Levels of NALF in the AR Model

Next, we examined cytokine levels in the NALF of OVA–wogonin-treated mice. The serum concentrations of IL-4, IL-5, and IL-13 were higher in the OVA group than in the control group (Fig. 3). Whereas the difference in serum IL-4 and IL-5 levels did not significantly differ between the wogonin and dexamethasone groups, IL-13 levels in the wogonin groups were significantly lower than in the OVA group.

Effect of Wogonin on Serum Cytokine Levels in the AR Model

Because allergic diseases are caused by the secretion of a series of Th2 cytokines, particularly IL-4, IL-5, and IL-13, we examined whether their levels were changed in OVA–wogonin-treated mice. The serum concentrations of IL-4, IL-5, and IL-13 were higher in the OVA group than in the control group (Fig. 3). Whereas the difference in serum IL-4 and IL-5 levels did not significantly differ between the wogonin and dexamethasone groups, IL-13 levels in the wogonin groups were significantly lower than in the OVA group.

Effect of Wogonin on Cytokine Levels of NALF in the AR Model

Next, we examined cytokine levels in the NALF of OVA–wogonin-treated mice. IL-4 and IL-5 levels in NALF were not significantly changed in the ovalbumin induced group compared with the normal control group (Fig. 4A and B). However, the difference in IL-4 and IL-5 levels in the groups administered wogonin differed significantly from those of normal control mice. As shown in Fig. 4C, IL-13 levels were elevated in mice with allergy (112.8 ± 14.5 pg/mL) compared with normal control mice (68.4 ± 7.3 pg/mL) but significantly lower in mice treated with wogonin 10 mg/mL (67.3 ± 7.0 pg/mL), wogonin 30 mg/mL (67.5 ± 2.5 pg/mL), or dexamethasone (58.4 ± 1.3 pg/mL). Eotaxin levels were higher in mice with allergy (80.0 ± 41.1 pg/mL) than in normal control mice (29.3 ± 2.9 pg/mL). By contrast, these levels were significantly lower in mice treated with wogonin at 10 and at 30 mg/mL (45.8 ± 12.3 pg/mL and 59.4 ± 2.7 pg/mL, respectively), and dexamethasone (45.1 ± 14.6 pg/mL) than in mice with allergy (p < 0.05) (Fig. 4D). The level of RANTES was also significantly reduced in mice treated with either the lower or higher dose of wogonin (32.3 ± 0.9 pg/mL and 31.2 ± 0.2 pg/mL, respectively) or with dexamethasone (30.0 ± 0.2 pg/mL) than in mice with allergy (p < 0.05) (Fig. 4E).

Immunohistochemistry of the Nasal Mucosa

IL-5 and IL-13 expression in the OVA-induced AR mouse model was measured by using immunohist-
chemistry. IL-5 expression in the nasal septum of the wogonin group was significantly lower than in the OVA group (Fig. 5). The decreased expression of IL-13 was relatively weak.

**DISCUSSION**

In this study, we showed that wogonin inhibited OVA-induced inflammation in a murine model of AR. Specifically, wogonin inhibited the levels of Th2-type cytokines.
inflammatory cytokines and reduced the number of eosinophils in the nasal mucosa. It also decreased OVA-specific IgE, IL-4, IL-5, and IL-13 levels in NALF as well as OVA-induced eotaxin and RANTES levels. AR is an inflammatory disease of the nasal mucosa characterized by the symptoms of nasal obstruction, sneezing, and rhinorrhea. OVA sensitization and challenge in animal models lead to an increase in the OVA-specific IgE and infiltration of inflammatory cells in the epithelium of the nasal mucosa.

The symptoms of AR are the product of an IgE-mediated inflammation of the nasal mucosa, which involves inflammatory cells. Eosinophils are the major inflammatory cell type that contributes to AR. They release proinflammatory mediators, such as Leukotriene C4 and platelet activating factor, which increase the permeability of mucosal cells and are potent chemotactic factors that stimulate further eosinophil infiltration. Eosinophils also produce large amounts of proteins that are toxic to respiratory epithelial cells. Th2 cells release cytokines, including IL-4, IL-5, and IL-13, all of which play important roles in allergic diseases. IL-4 and IL-13 promote IgE production by B cells and mucus production in the airways. IL-4 also induces the activation of T cells and their differentiation into the Th2 subtype. IL-5 plays a critical role in the generation and release of eosinophils in the bone marrow, whereas eotaxin promotes the selective recruitment of eosinophils into the inflamed area. As shown in Fig. 4, A–C, wogonin reduced Th2 cytokine production (IL-4, IL-5, and IL-13) in NALF and thus demonstrated antiallergic effects.

Wogonin is one of several compounds from *S. baicalensis* with a proven anti-inflammatory effect. A recent study of a murine model of allergic asthma showed that the potent activity of wogonin involves the regulation of the IL-4/signal transducer and activator of transcription 6 signaling pathway. In this study, wogonin treatment inhibited Th2 responses, thereby reducing IL-4 and IL-5, and attenuated allergic inflammation. Airway epithelial cells release high levels of eotaxin when stimulated with IL-4 or IL-13. IgE produced by B cells stimulated with IL-4 and IL-13 binds to mast cell receptors. The subsequently activated mast cells produce a variety of mediators and cytokines that contribute to the characteristic allergic responses, including the release of chemokines, cytokines, and growth factors by epithelial cells. This response promotes persistent late-stage allergic reactions and progressive allergic inflammation. Our results, obtained in a murine model of AR, indicated that the reduction of allergic inflammation by wogonin was related to a decrease in Th2 cytokine production, tissue eosinophilia, and production of OVA-specific IgE. These findings indicated the potential anti-inflammatory role of wogonin as an inhibitor of OVA-specific allergic responses in the nasal mucosa.

CONCLUSION

Wogonin suppressed allergic cytokines in a murine model of AR. Its anti-inflammatory activity is mediated by a decrease in eosinophil migration into the nasal mucosa and inhibition of serum IgE and of nasal IL-4, IL-5, and IL-13 levels. Our study demonstrated the antiallergic effect of wogonin in an *in vivo* model of AR.
AR, and, thus, by extension, the potential therapeutic utility of wogonin in treating AR in humans.

ETHICAL APPROVAL
This study was approved by the Institutional Review Board of Gachon University Gil Medical Center (approval number: GCIRB2014-362).

STATEMENT OF HUMAN AND ANIMAL RIGHTS
This article does not contain any studies with human or animal subjects.

STATEMENT OF INFORMED CONSENT
There are no human subjects in this article and informed consent is not applicable.

REFERENCES
1. Skoner DP. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001; 108(suppl.):S2–S8.
2. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998; 351:1225–1232.
3. Suh M, Kim HH, Sohn MH, et al. Prevalence of allergic diseases among Korean school-age children: A nationwide cross-sectional questionnaire study. J Korean Med Sci. 2011; 26:332–338.
4. Park HS, Choi GS, Cho JS, Kim YY. Epidemiology and current status of allergic rhinitis, asthma, and associated allergic diseases in Korea: ARIA Asia-Pacific workshop report. Asian Pac J Allergy Immunol. 2009; 27:167–171.
5. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63(suppl. 86):S8–160.
6. Fineman SM. The burden of allergic rhinitis: Beyond dollars and cents. Ann Allergy Asthma Immunol. 2002; 88:2–7.
7. Price D, Zhang Q, Kocevar VS, et al. Effect of a concomitant allergen upregulates the local expression of vascular endothelial growth factor receptors and by activating neutrophils. Am J Physiol Lung Cell Mol Physiol. 2001; 280:L134–L140.
8. Howarth PH, Persson CG, Meltzer EO, et al. Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol. 2005; 115(suppl. 1):S414–S441.
9. Church MK, Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol. 1997; 99:155–160.
10. Lee BJ, Naclerio RM, Bochner BS, et al. Nasal challenge with allergen upregulates the local expression of vascular endothelial adhesion molecules. J Allergy Clin Immunol. 1994; 94:1006–1016.
11. Blanc PD, Trupin L, Earnest G, et al. Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: Data from a population-based survey. Chest. 2001; 120:1461–1467.
12. Markham AW, Wilkinson JM. Complementary and alternative medicines (CAM) in the management of asthma: An examination of the evidence. J Asthma. 2004; 41:131–139.
13. Shao ZH, Li CQ, Vanden Hoek TL, et al. Extract from Scutellaria baicalensis Georgi attenuates oxidant stress in cardiomyocytes. J Mol Cell Cardiol. 1999; 31:1885–1895.
14. Tai MC, Tsang SY, Chang LY, Xue H. Therapeutic potential of wogonin: A naturally occurring flavonoid. CNS Drug Rev. 2005; 11:141–150.
15. Lin CM, Chang H, Chen YH, et al. Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1. Int Immunopharmacol. 2006; 6:1690–1698.
16. Li-Weber M. New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev. 2009; 35:57–68.
17. Lee W, Ku SK, Bae JS. Anti-inflammatory effects of Baicalin, Baicalein, and Wogonin in vitro and in vivo. Inflammation. 2015; 38:110–125.
18. Hsu HY. Oriental Materia Medica: A Concise Guide. Long Beach, CA: Oriental Healing Arts Institute. 1986; 1–10.
19. Huang WH, Lee AR, Yang CH. Antioxidative and anti-inflammatory activities of polyhydroxyflavonoids of Scutellaria baicalensis GIEORG. Biocent Biotechnol Biochem. 2006; 70:2371–2380.
20. de Benedictis FM, Bush A. Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med. 2012; 185:12–23.
21. Hellings PW, Ceuppens JL. Mouse models of global airway allergy: What have we learned and what should we do next? Allergy. 2004; 59:914–919.
22. Jeffery PK, Haahelta T. Allergic rhinitis and asthma: Inflammation in a one-airway condition. BMC Pulm Med. 2006; 30(suppl. 1):S5.
23. Bahekar PC, Shah JH, Ayer UB, Mandhane SN. Validation of guinea pig model of allergic rhinitis by oral and topical drugs. Int Immunopharmacol. 2008; 8:1540–1551.
24. Possa SS, Leick EA, Prado CM, et al. Eosinophilic inflammation in allergic asthma. Front Pharmacol. 2013; 4:46.
25. Yssel H, Groux H. Characterization of T cell subpopulations involved in the pathogenesis of asthma and allergic diseases. Int Arch Allergy Immunol. 2000; 121:10–18.
26. Shim JJ, Dabbagh K, Ueki IF, et al. IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. Am J Physiol Lung Cell Mol Physiol. 2001; 280:L134–L140.
27. Frew AJ. The immunology of respiratory allergies. Toxicol Lett. 1996; 86:65–72.
28. Corr CM. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med. 2012; 13:305–312.
29. Walsh GM. Targeting eosinophils in asthma: Current and future state of cytokine and chemokine-directed monoclonal therapy. Expert Rev Clin Immunol. 2010; 6:701–704.
30. Lim BO. Efficacy of wogonin in the production of immunoglobulins and cytokines by mesenteric lymph node lymphocytes in mouse colitis induced with dextran sulfate sodium. Biosci Biotechnol Biochem. 2004; 68:2505–2511.
31. Ryu EK, Kim TH, Jang EJ, et al. Wogonin, a plant flavone from Scutellaria radix, attenuated ovalbumin-induced airway inflammation in mouse model of asthma via the suppression of IL-4/STAT6 signaling. J Clin Biochem Nutr. 2015; 57:105–112.
32. Banwell ME, Tolley NS, Williams TJ, Mitchell TJ. Regulation of human eosinophil-3/CCL26 expression: Modulation by cytokines and glucocorticoids. Cytokine. 2002; 17:317–323.
33. Komiya A, Nagase H, Yamada H, et al. Concerted expression of IL-4/STAT6 signaling. J Clin Biochem Nutr. 2015; 57:105–112.
34. Galili SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012; 18:693–704.
35. Mayr SI, Zuberi RI, Zhang M, et al. IgE-dependent mast cell activation potentiates airway responses in murine asthma model. J Immunol. 2002; 169:2061–2068.
36. Westergren VS, Wilson SJ, Penrose JF, et al. Nasal mucosal expression of the leukotriene and prostaglandin pathways in seasonal and perennial allergic rhinitis. Clin Exp Allergy. 2009; 39:820–828.
37. Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: Biological properties and role in health and disease. Clin Exp Allergy. 2008; 38:709–750.